Categories: News

Webinar: Piezo Motion’s Miniature Motors Are Driving Next Generation of Medical Devices

On April 21, Dr. Mark Broderick will discuss how Piezo Motion is revolutionizing the miniature-motor industry and providing viable solutions in high-tech industries

LAKEWOOD RANCH, Fla., April 07, 2022 (GLOBE NEWSWIRE) — via InvestorWire — On April 21, Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, will host a webinar discussing its miniature precision motors and the new opportunities they create for medical devices and high-tech industries.

Dr. Mark Broderick, Ph.D., will analyze the stability and accuracy of Piezo Motion’s multifaceted rotary and linear miniature motors, designed specifically for medical device manufacturers requiring improved speed, size and accuracy.

“Our motion solutions are enabling a new generation of high tech and medical devices,” said Hassan Kotob, chairman and CEO of Brain Scientific. “Traditionally, 3D printer manufacturers and laser optics companies have turned to us to take advantage of our compact, high-precision and energy-efficient motors. More recently, blood pressure monitors, portable infusion pumps, and medical robot developers have been pushing the envelope prototyping our tiny non-magnetic motors for their next-generation devices.”

Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, industrial electronic and automotive systems, and an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.

To register for the April 21 webinar, click here: Tiny Piezomotor Creates New Opportunities for Motion Control Within Medical Device and Hi-Tech Industries 

About Piezo Motion

Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.

About Brain Scientific

Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements. 

CONTACTS

INVESTORS
ir@brainscientific.com

MEDIA
pr@brainscientific.com

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Staff

Recent Posts

Masimo Responds to Politan’s Continuing Misrepresentations

IRVINE, Calif.--(BUSINESS WIRE)--To ensure that Politan lies repeated over and over are not taken as…

48 mins ago

Complete Care Lakeview Announces Name Change to Complete Care Wayne Hills Rehab & Respiratory Center

WAYNE, NJ / ACCESSWIRE / July 15, 2024 / Complete Care Lakeview, a leading provider…

51 mins ago

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short…

51 mins ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL…

52 mins ago

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of…

52 mins ago